Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Google Secures Pentagon AI Deal for Classified Projects 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
AMSTERDAM, the Netherlands, Feb. 15, 2016 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference on February 24, 2016 at 2:05 p.m. EST / 20:05 pm CET. The conference is being held February 23 - 24, 2016 at The Palace Hotel in New York City.
The webcast, including a slide presentation, can be accessed through the following link: http://www.veracast.com/webcasts/rbc/healthcare2016/26211430508.cfm or by accessing the link displayed in the "Events" section on the "Media" page of the uniQure website at: http://www.uniqure.com/news/calendar-of-events/. The replay of the webcast will be available one hour after the conclusion of the live event and archived on the uniQure website for at least 30 days following the webcast.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Eva Mulder
Direct : +31 20 240 6103
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
